Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
May Choi¹, Hongshu Guan², Kazuki Yoshida³, Benjamin Kargere⁴, Jack Ellrodt⁵, Emma Stevens², Tianrun Cai², Brendan Everett², Brittany Weber² and Karen Costenbader⁶, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Takeda, Boston, MA, ⁴Williams College, Boston, MA, ⁵Williams College, Williamstown, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
Abstract Number: 0889 • ACR Convergence 2023
Axl Receptor Tyrosine Kinase Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization
Wenwen Pei¹, Ranran Yao¹, Ziye Wang², Ruyu Liang³, Renge Liang², Xiaolin Sun⁴ and Yin Su², ¹Peking University, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Peking University, XiCheng, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: Diffusealveolar hemorrhage (DAH) is an infrequent but life-threatening complication in patients with systemic lupus erythematosus (SLE). Cells of the monocyte/macrophage lineage are essential to…
Abstract Number: 0909 • ACR Convergence 2023
Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Joy Park¹, Xiaojing Wang², Aparna Godavarthy¹, Akshay Patel², Krakko Daniel¹, Jessica Nolan¹, Joanne Chilton¹, Bryan Blaker¹ and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Aastha Khatiwada¹, bethany wolf², Isabelle Ayoub³, Juan Mejia-Vilet⁴, Ana Malvar⁵, Carl Langefeld⁶, Brad Rovin³, Jim Oates² and Betty Tsao², ¹National Jewish Health, Denver, CO, ²Medical University of South Carolina, Charleston, SC, ³Ohio State University, Columbus, OH, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Hospital Fernandez, Buenos Aires, Argentina, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
Abstract Number: 1224 • ACR Convergence 2023
Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic
Audrea Chen¹, Tala El Tal², Asha Jeyanathan¹, Holly Convery¹, Stephanie Wong¹, Linda Hiraki¹, Deborah Levy¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 1452 • ACR Convergence 2023
Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Audrey Hagiwara, Moumita Bose, Marianne Bernardo, Michael Nelson, Mariko Ishimori, Daniel Berman, C. Noel Bairey Merz, janet wei and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Women with SLE have an elevated risk of cardiovascular disease. Many women with SLE frequently report chest pain in the absence of obstructive coronary…
Abstract Number: 1469 • ACR Convergence 2023
Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Daniel Joyce¹, Jeffrey. Berger², Allison Guttmann³, Ghadeer Hasan⁴, Jill Buyon⁵, H Michael Belmont¹, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles Helmick¹⁴, Kamil Barbour¹⁵, Heather Gold¹⁶, Hilary Parton¹⁷ and Peter Izmirly², ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Atlantic Health System, Summit, NJ, ⁴Optum, Jersey City, NJ, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹SUNY Downstate Health Sciences University, Brooklyn, NY, ¹²Albert Einstein College of Medicine, Bronx, NY, ¹³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁴NA, Atlanta, GA, ¹⁵Centers for Disease Control and Prevention, Atlanta, GA, ¹⁶New York University, New York, NY, ¹⁷New York City Department of Health and Mental Hygiene, Queens, NY
Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…
Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
Abstract Number: 1503 • ACR Convergence 2023
Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data
Christian Stach¹, Caroline Gordon², Vanessa Taieb³, George Stojan⁴ and Joan Merrill⁵, ¹UCB Pharma, Monheim am Rheim, Germany, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ³UCB Pharma, Colombes, France, ⁴UCB, Baltimore, MD, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo responses pose challenges to systemic lupus erythematosus (SLE) clinical trials.1This analysis aims to identify predictors of standard of care plus placebo (SOC+PBO)…
Abstract Number: 1600 • ACR Convergence 2023
Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes
Jasmine Shwetar¹, Katie Preisinger¹, Devyn Zaminski², Philip Carlucci¹, Kristina Deonaraine¹, Qian Xiao³, Joseph Mears⁴, Siddarth Gurajala³, Izmirly peter⁵, Judith James⁶, Joel Guthridge⁶, Andrea Fava⁷, Brad Rovin⁸, Wade DeJager⁶, Ming Wu⁹, Deepak Rao¹⁰, Chaim Putterman¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont², William Apruzzese¹⁰, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹⁰, Celine Berthier¹⁷, Maria Dall'Era¹⁸, Kerry Cho¹⁹, Diane L. Kamen²⁰, Kenneth Kalunian²¹, Jennifer Anolik²², Soumya Raychaudhuri¹⁰, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, David Wofsy¹⁸, Arnon Arazi²⁶, Kelly Ruggles⁹, Jill Buyon²⁵ and The Accelerating Medicines Partnership SLE/RA²⁷, ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU, New York, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Johns Hopkins University, Baltimore, MD, ⁸Ohio State University, Columbus, OH, ⁹NYU Langone, New York, NY, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of California San Francisco, San Francisco, CA, ¹⁹UCSF Health, San Francisco, CA, ²⁰Medical University of South Carolina, Charleston, SC, ²¹University of California San Diego, La Jolla, CA, ²²University of Rochester Medical Center, Rochester, NY, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Broad Institute of MIT and Harvard, Melrose, MA, ²⁷University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Lupus Nephritis (LN) significantly reduces the survival and life expectancy of patients with SLE. Given this, considerable effort has gone into characterizing the histologic…
Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 2035 • ACR Convergence 2023
Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous
Emmanuel Campos-Tinajero¹, Griselda Serna-Peña², Jorge A. Esquivel-Valerio¹, Rodrigo J. Castillo-de la Garza³, Gisela García Arellano⁴, Pablo Gamez-Siller¹, Estefania Aguilar-Rivera⁵, Patricia L. Gonzalez-Garcia¹ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, multisystemic, chronic disease more prevalent in women and can significantly impact health-related quality of life (HRQoL).1 Sociodemographic…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
J. Patricia Dhar¹, Hannah Forsythe², Louis Saravolatz¹ and Susanna Szpunar³, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St. John Hospital, Detroit, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.